Algenex and Virbac sign an international commercial license agreement for CrisBio®Pig-based vaccine

Madrid (Spain) and Carros (France), February 22, 2021 – Algenex SL, a VC-backed biotechnology company that supplies disruptive technologies for the production of recombinant biologics, and Virbac, the sixth largest animal health company in the world, today announced that they have signed an international license agreement to develop and commercialize a CrisBio®. Vaccine based on an important pig indication.

The vaccine is co-developed and manufactured using CrisBio®, Algenex’s proprietary and patented baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural, single-use bioreactors. CrisBio® represents a new paradigm in the production of biologics and offers a fast, linearly scalable solution to meet the global demand for recombinant protein production without significant investments. Algenex expects European approval of the first veterinary vaccine made with CrisBio in 2021.

“This new collaboration with Virbac, one of the world’s leading animal health companies, is another important milestone for Algenex and further validation of our unique CrisBio® technology and its potential to transform vaccine production in key animal health indications,” said Claudia Jiménez, CEO of Algenex.

“With this partnership, we will benefit from Algenex’s experience and improve our livestock footprint by providing a simple, scalable and cost-effective alternative to current bioreactor-based expression technologies in the market.” Vaccine market, “said Sébastien Huron, CEO of Virbac -Group.

Commercial and financial terms of the agreement were not disclosed. The agreement covers all global markets with the exception of Poland and Italy.

For more information please contact:

Algenex contact Virbac contact
Claudia Jiménez Manuela Rodriguez
CEO Director of Investor Relations
T: +34 91 452 4941 T: +33 (0) 6 22 52 42 55

About Algenex

Algenex is a VC-backed biotechnology company developing disruptive baculovirus-based technologies to manufacture recombinant biologics. Algenex’s first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have shown that they can transform recombinant protein production through a process that has near-limitless and instant linear scalability of manufacture, production flexibility, simplicity and Offers versatility and at the same time extremely cost-effective.

Algenex has successfully manufactured> 200 molecules in collaboration with public and private partners including several international pharmaceutical companies including VLPs, monomeric vaccines, diagnostic reagents, enzymes and growth factors.

More information is available at

About Virbac

Focused on animal health from the start. At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Our range of products and services covers more than 50 types and enables the diagnosis, prevention and treatment of most pathologies. Every day we work to improve the quality of life for animals and to shape the future of animal health together.

For more information, please visit